Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow growth accelerates

Q3 FY2026 financing cash flow of $550.16M rose 187.1% year over year, ahead of the +115.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 37098.0% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +187.1% holds above the trailing-twelve-month pace of +115.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$550.16M+37098.0% QoQ
Last fiscal yearDec 2025
$257.03M+73758.9% YoY
LTMSep 2026
$554.65M+115.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+187.1%——
1 year+73758.9%——
3-year CAGR-15.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
257.03M USD
Year-over-year change
+73758.9%
4-year CAGR
+12.8%

Financing Cash Flow vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +115.5% is the 7th highest of 10, against a peer median of +256.9%.
  • Over three fiscal years its annual growth of -15.9% compares with a peer median of -11.4%.
AMLX Competitors
Financing Cash Flow for AMLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$1.23B USD+505.2%+306.4%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$554.65M USD+115.5%-15.9%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$425.38M USD+1810.7%-15.2%11803.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$261.93M USD+546.0%—27.3%
PMNProMIS Neurosciences, Inc.LTM Jun 2026$91.07M USD+234.5%+33.9%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$53.69M USD-59.8%——
AVXLAnavex Life Sciences Corp.LTM Dec 2025$45.05M USD+256.9%-23.8%—
CLNNClene Inc.LTM Mar 2026$14.08M USD+1110.6%-12.6%10506.7%
PRTAProthena Corporation plcLTM Mar 2026$7.03M USD-1150.0%—12.1%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
Peer median (excluding AMLX) —+256.9%-11.4%28.5%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Depreciation & Amortization52K487K1.09M904K525K
Deferred Income Tax00000
Stock-Based Compensation3.14M21.71M37.16M33.04M27.65M
Change in Working Capital4.6M(1.64M)(65.66M)(45.83M)(1.08M)
Accounts Receivables(144K)(15.31M)(24.74M)39.6M383K
Inventory0(9.77M)(73.13M)(9.25M)0
Accounts Payables670K1.85M15.88M(19.1M)580K
Other Working Capital4.07M21.58M16.33M(57.08M)(2.05M)
Other Non-Cash Items5.35M(2.06M)(9.94M)145.99M(5.7M)
Operating Cash Flow(74.8M)(179.87M)11.92M(167.65M)(123.34M)
Capital Expenditures(353K)(2.53M)(1.24M)(157K)(138K)
Acquisitions (Net)0236.46M000
Purchases of Investments(49.05M)(415.87M)(300.83M)(231.99M)(231.82M)
Sales of Investments3M179.41M394.12M344M246M
Other Investing Activities0(236.46M)0(36.2M)0
Investing Cash Flow(46.41M)(238.99M)92.05M75.65M14.04M
Debt Repayment25.9M0000
Common Stock Issued0432.45M6.86M2.13M260.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.39M)(658K)(3.32M)(1.78M)(3.36M)
Financing Cash Flow158.51M431.79M3.54M348K257.03M
Effect of Forex Changes13K(65K)160K(438K)1.07M
Net Change in Cash37.31M12.87M107.68M(92.08M)148.8M
Free Cash Flow(75.15M)(182.4M)10.68M(167.8M)(123.48M)

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.